Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
This article was originally published in The Pink Sheet Daily
With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.
You may also be interested in...
While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
Just two years after Sanofi-Aventis SA set out to reinvent itself as the flexible, entrepreneurial, easy-partnering, globally diversified health care leader of the future, the French pharma has mounted a grassroots campaign to familiarize the academic/biotech community with its new Therapeutic Strategy Units, a handful of targeted areas with high unmet need and commensurately huge opportunity that are part of Sanofi's long-range R&D strategy.